Insights
8 October 2026
|10 min read
How to assess cytokine release and immunogenicity risk in vitro before first-in-human dosing, which ADA assays are needed and what the guidance says.
Insights
30 September 2026
|12 min read
What in vitro pharmacology data do you need for a biologic IND filing? A practical guide to mechanism of action, potency, species relevance, immune safety and ICH S6(R1).
Insights
4 September 2026
|7 min read
RoukenBio’s human donor-derived air-liquid interface (ALI) asthma model recreates key features of Type 2 airway inflammation, including mucus production and epithelial remodelling. Discover how this translational platform supports target validation, biomarker analysis and therapeutic evaluation in asthma drug discovery.
Research Posters
17 August 2026
|4 min read
This research poster presents a high-throughput, patient-derived colorectal cancer tumoroid platform incorporating autologous fibroblasts and tumour-infiltrating lymphocytes. By combining genomic, gene-expression and drug-response data, the model captures patient-specific tumour heterogeneity and supports translational drug discovery, predictive biomarker identification and immunotherapy research.
🗓️ Stay informed with our monthly scientific newsletter, published on LinkedIn on the last Wednesday of each month.
These editions bring you the latest in drug development breakthroughs, industry trends, and expert insights from the brilliant minds at RoukenBio.
Subscribe today on LinkedInDifficulty doesn’t deter us; it inspires us. Give us a problem, and we’ll find your solution. Our versatile specialists embrace every obstacle as an opportunity to showcase our innovative thinking and problem-solving prowess.
